Figure 1

Relations between effects of tocilizumab on the proportion of regulatory T cells and clinical responses. (A) Chronological change in the proportion of regulatory T (T_reg) cells among CD4⁺ T cells from baseline to week 52 of tocilizumab (TCZ) treatment. (B) The relationships between the change in clinical activities (Clinical Disease Activity Index (ΔCDAI) and Simplified Disease Activity Index (ΔSDAI)) and the change in proportion of T_reg cells among CD4+ T cells (ΔT_reg/CD4) at week 52. (C) The relationships between CDAI and SDAI scores at week 52 and the change in proportion of T_reg cells among CD4⁺ T cells (ΔT_reg/CD4) at week 52. (D) The relationships between CDAI and SDAI scores at week 52 and the proportion of T_reg cells among CD4⁺ T cells at week 52. The squares signify medians and interquartile ranges, and the diamonds signify means and 95% confidence intervals. Data were analyzed by using the Kruskal-Wallis test (A), Spearman’s rank correlation coefficient (B) and the Wilcoxon rank-sum test (C,D). *Significant differences.